Vincerx Pharma, Inc. financial data

Symbol
VINC on OTC
Location
Palo Alto, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q1 2025 - 15 May 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 220% % -2%
Debt-to-equity 68% % -16%
Return On Equity -309% % -2.7%
Return On Assets -184% % -10%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5,234,277 shares -76%
Common Stock, Shares, Outstanding 5,234,277 shares -76%
Entity Public Float $21,000,000 USD -8.7%
Common Stock, Value, Issued $1,000 USD -50%
Weighted Average Number of Shares Outstanding, Basic 3,580 shares 230%
Weighted Average Number of Shares Outstanding, Diluted 3,580 shares 230%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense $15,371,000 USD 27%
Operating Income (Loss) $27,319,000 USD 21%
Nonoperating Income (Expense) $4,674,000 USD 66%
Net Income (Loss) Attributable to Parent $22,645,000 USD 40%
Earnings Per Share, Basic -6 USD/shares 88%
Earnings Per Share, Diluted -6 USD/shares 88%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $4,437,000 USD -13%
Marketable Securities, Current $7,144,000 USD 25%
Other Assets, Current $44,000 USD -94%
Assets, Current $4,686,000 USD -39%
Property, Plant and Equipment, Net $0 USD -100%
Operating Lease, Right-of-Use Asset $0 USD -100%
Other Assets, Noncurrent $1,595,000 USD 38%
Assets $4,686,000 USD -58%
Accounts Payable, Current $2,269,000 USD -1.9%
Accrued Liabilities, Current $351,000 USD -80%
Liabilities, Current $2,620,000 USD -75%
Operating Lease, Liability, Noncurrent $0 USD -100%
Other Liabilities, Noncurrent $0 USD -100%
Liabilities $2,620,000 USD -78%
Accumulated Other Comprehensive Income (Loss), Net of Tax $170,000 USD 183%
Retained Earnings (Accumulated Deficit) $194,186,000 USD -13%
Stockholders' Equity Attributable to Parent $2,066,000 USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $2,500,000,000 USD
Liabilities and Equity $4,686,000 USD -58%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $4,454,000 USD 42%
Net Cash Provided by (Used in) Financing Activities $3,856,000 USD 77020%
Net Cash Provided by (Used in) Investing Activities $0 USD -100%
Common Stock, Shares Authorized 120,000,000 shares 0%
Common Stock, Shares, Issued 5,234,277 shares -76%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $547,000 USD 93%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4,519,000 USD -13%
Interest Paid, Excluding Capitalized Interest, Operating Activities $0 USD
Deferred Tax Assets, Valuation Allowance $40,954,000 USD 8.5%
Deferred Tax Assets, Gross $40,954,000 USD 7%
Operating Lease, Liability $1,639,000 USD -41%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $22,535,000 USD 41%
Property, Plant and Equipment, Gross $0 USD -100%
Operating Lease, Liability, Current $0 USD -100%
Operating Lease, Weighted Average Discount Rate, Percent 0 pure -100%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $90,000 USD -67%
Deferred Tax Assets, Operating Loss Carryforwards $19,357,000 USD 25%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 30,000,000 shares 0%
Unrecognized Tax Benefits $1,540,000 USD 24%
Operating Lease, Payments $990,000 USD -23%
Additional Paid in Capital $196,081,000 USD 15%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $0 USD -100%
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $3,380,000 USD 25%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%